GlassScriptPhysician profile
Dustin Blake Kempf
NPI 1578069548
$2,118.62
in general payments reported to CMS, 2019-2025
21 companies · $28.47 in 2025
The $28.47 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.27 · 2022: $401 · 2023: $1,242 · 2024: $415 · 2025: $28.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,685.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $324.82 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $295.61 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $273.92 | 2021-2024 | Invega Sustenna |
| Alkermes, INC. | $252.26 | 2022-2024 | Aristada, Lybalvi |
| Corium, LLC | $200.69 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $141.97 | 2022-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $141.73 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Supernus Pharmaceuticals, INC. | $95.54 | 2022-2023 | |
| Axsome Therapeutics, INC. | $80.00 | 2023-2024 | Auvelity |
| Lundbeck LLC | $78.76 | 2022-2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $62.32 | 2022-2024 | Jornay Pm |
| Sage Therapeutics, LLC | $28.08 | 2024 | |
| Tempus Ai, INC | $21.90 | 2024 | |
| Idorsia Pharmaceuticals US INC | $18.66 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $17.63 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.62 | 2022 | |
| Indivior INC. | $14.98 | 2024 | Perseris |
| Abbvie INC. | $14.95 | 2023 | |
| Tris Pharma INC | $14.28 | 2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $13.65 | 2023 | Trintellix |
| Neuronetics, INC. | $10.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Kempf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.